Guggenheim raises Elevance Health target. Elevance Health stock gains 1.89 percent.

Published on 10/21/2026 at 11:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Guggenheim lifted its target to USD 460 on October 12, 2026. Elevance Health stock costs EUR 389.00, 1.89 percent above the Xetra close of October 20, 2026.

Target and results setup

Guggenheim raised its Elevance Health target from USD 455.00 to USD 460.00 on October 12, 2026.
Second-quarter revenue reached USD 49.83 billion for the period ended June 30, 2026.
Elevance Health stock trades at EUR 389.00 at 11:39 a.m. CEST at Lang & Schwarz on October 21, 2026, 1.89 percent above the Xetra close of October 20, 2026.

Draufsicht-Arrangement mit Aktienzertifikat, ISIN-Karte US2855211023 und Stethoskop — Elevance Health US2855211023 Flatlay mit Aktienzertifikat ISIN-Karte Stethoskop und medizinischen Utensilien auf Marmor, Illustration mit AI erstellt.

Elevance Health (ISIN US0367521038) was trading at EUR 389.00 at Lang & Schwarz on October 21, 2026, at 11:39 a.m. CEST, 1.89 percent above the Xetra close of October 20, 2026 at EUR 381.80. The insurer was due to report third-quarter results before the US market opened, while Guggenheim had raised its target from USD 455.00 to USD 460.00 on October 12, 2026, according to Gekko.

Results put margins in focus

Elevance Health's second-quarter revenue reached USD 49.83 billion for the period ended June 30, 2026, according to Yahoo Finance. That figure was flat year over year in the report cited by the outlet, making the third-quarter revenue outlook a central test for the stock after a period of sharp earnings comparisons.

Three dates shape the story

On July 15, 2026, Elevance Health reported quarterly earnings of USD 7.45 per share and revenue of USD 49.83 billion, according to MarketBeat. On October 12, 2026, Guggenheim lifted its target from USD 455.00 to USD 460.00. On October 21, 2026, Elevance Health was scheduled to report third-quarter results at 6:00 a.m. EDT, according to SignalStack.

What does the target imply?

Guggenheim's USD 460.00 target stood 4.50 percent above the USD 440.18 US closing price from October 20, 2026. That spread is smaller than the gap between the target and the October 21 euro indication, so the scheduled results and the company's margin trajectory remain the immediate valuation tests.

Next reporting date is October 21

The next substantiated company date was October 21, 2026, for the third-quarter earnings release before the market opened. For investors, the key comparison is whether revenue can hold near the USD 49.83 billion second-quarter level while earnings absorb seasonal pressure.

Stock holds above the Xetra close

The NYSE listing had closed at USD 440.18 on October 20, 2026, while the euro quotation was higher than the prior Xetra reference after the pre-reporting move. The stock's USD 274.84 to USD 440.67 52-week range and USD 95.5 billion market capitalization were both stated as of October 20, 2026.

Elevance Health was trading at EUR 389.00 at Lang & Schwarz on October 21, 2026, at 11:39 a.m. CEST, 1.89 percent above the Xetra close of October 20, 2026 at EUR 381.80. The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.